BACKGROUND: Retrospective single-centre series have shown the feasibility of sentinel lymph-node (SLN) identification in @entity1204 . We did a prospective, multicentre cohort study to assess the detection rate and diagnostic accuracy of the SLN procedure in predicting the pathological pelvic-node status in @entity1 with early stage @entity1204 . METHODS: @entity1 with International Federation of Gynecology and Obstetrics (FIGO) stage I-II @entity1204 had pelvic SLN assessment via cervical dual injection (with @entity1136 and patent blue), and systematic pelvic-node dissection. All lymph nodes were histopathologically examined and SLNs were serial sectioned and examined by immunochemistry. The primary endpoint was estimation of the negative predictive value (NPV) of @entity1817 per hemipelvis. This is an ongoing study for which recruitment has ended. The study is registered with ClinicalTrials.gov, number NCT00987051. FINDINGS: From July 5, 2007, to Aug 4, 2009, 133 @entity1 were enrolled at nine centres in France. No complications occurred after injection of @entity1136 colloid and no anaphylactic reactions were noted after patent blue injection. No surgical complications were reported during SLN biopsy, including procedures that involved conversion to open surgery. At least one SLN was detected in 111 of the 125 eligible @entity1 . 19 of 111 (17%) had pelvic-lymph-node @entity3 . Five of 111 @entity1 (5%) had an associated SLN in the para-aortic area. Considering the hemipelvis as the unit of analysis, NPV was 100% (95% CI 95-100) and sensitivity 100% (63-100). Considering the @entity1 as the unit of analysis, three @entity1 had false-negative results (two had metastatic nodes in the contralateral pelvic area and one in the para-aortic area), giving an NPV of 97% (95% CI 91-99) and sensitivity of 84% (62-95). All three of these @entity1 had type 2 @entity1204 . Immunohistochemistry and serial sectioning detected @entity3 undiagnosed by conventional histology in nine of 111 (8%) @entity1 with detected SLNs, representing nine of the 19 @entity1 (47%) with @entity3 . SLN biopsy upstaged 10% of @entity1 with low-risk and 15% of those with intermediate-risk @entity1204 . INTERPRETATION: SLN biopsy with cervical dual labelling could be a trade-off between systematic lymphadenectomy and no dissection at all in @entity1 with @entity1204 of low or intermediate risk. Moreover, our study suggests that SLN biopsy could provide important data to tailor adjuvant therapy. FUNDING: Direction Interr  gionale de Recherche Clinique, Ile-de-France, Assistance Publique-H  pitaux de Paris.

Detection rate and diagnostic accuracy of @entity1817 in early stage XXXX : a prospective multicentre study (SENTI-ENDO).

@entity1204 :: ('MESH:D016889', 'Disease') :: ['endometrial cancer'] @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity1136 :: ('MESH:D013667', 'Chemical') :: ['technetium'] @entity1817 :: ('MESH:D012804', 'Disease') :: ['sentinel-node biopsy'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']
@entity1204 :: (MESH:D016889,Disease) :: ['endometrial cancer']
